NBTY shareholder lawsuit
This article was originally published in The Tan Sheet
Executive Summary
Central Islip, N.Y. federal Judge Arthur Spatt dismisses consolidated shareholder class action against dietary supplement firm due to failure to adequately plead fraud. In Sept. 28 opinion, court says plaintiffs' allegations that NBTY failed to disclose several known adverse trends affecting company's financial health, including dramatic weakening in its retail sector, are "conclusory and insufficiently supported by the facts." Plaintiffs have 30 days to amend the complaint. Action was filed on behalf of purchasers of NBTY common stock between Jan. 27, 2000 and June 15, 2000, and alleged the company, certain officers and directors failed to disclose material facts that resulted in a drop in firm's stock price (1"The Tan Sheet" Aug. 14, 2000, p. 2)...
You may also be interested in...
NBTY
Vitamin/supplement maker and several execs named defendants in a shareholder class action suit filed July 28 in Uniondale, N.Y. federal court on behalf of purchasers of NBTY stock between Jan. 27 and June 15. The lawsuit alleges the defendants, during the period in question, failed to disclose several adverse factors, including declining Vitamin World same-store sales due to a negative industry-wide trend and a negative impact on financial results from U.K. operations caused by fluctuation in the British pound sterling. The lawsuit alleges NBTY's stock dropped 36% following a June 15 company announcement regarding same-store sales and foreign currency weaknesses (1"The Tan Sheet" July 17, p. 10)
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.